Ripasudil as a Potential Therapeutic Agent in Treating Secondary Glaucoma in HTLV-1-Uveitis: An In Vitro Analysis

Non-cancerous complications in HTLV-1 carriers

Expert Rev Anti Infect Ther. 2024 Mar 27. doi: 10.1080/14787210.2024.2336547. Online ahead of print. ABSTRACT INTRODUCTION: Human T-cell leukemia virus type 1 (HTLV-1) carriers may develop adult T-cell leukemia (ATL), or HTLV-1-associated myelopathy (HAM)/tropical...
Ripasudil as a Potential Therapeutic Agent in Treating Secondary Glaucoma in HTLV-1-Uveitis: An In Vitro Analysis

HTLV in Sweden

AIDS Rev. 2024;26(1):41-47. doi: 10.24875/AIDSRev.24000002. ABSTRACT Sweden is a country with a low prevalence of human lymphotropic T-cell virus (HTLV) infection, estimated at < 0.005%, but the infection rate is notably higher in specific risk groups such as...